Free Newsletter
Gene abnormality linked to Alzheimer's
Abnormalities in the SORL1 gene have been linked to Alzheimer's in what is being billed as a major advance in understanding the origins of the memory-wasting disease. Scientists in the study examined the cases of 6,000 patients and found the genetic mutation appeared to be responsible for a large number of cases of late-onset Alzheimer's, the most common form of the disease. When the SORL1 gene is working properly, it prevents the amyloid precursor protein from becoming toxic. But when the gene is deficient, it allows the amyloid beta peptide to accumulate and foster amyloid plaques linked to Alzheimer's. A mutation of ApoE4 has been linked to about 20 percent of Alzheimer's cases. Researchers said that other genetic variants were also likely to be behind Alzheimer's.
- check out the Sydney Morning Herald report on the gene research
Related Articles:
Enzyme essential to preventing Alzheimer's. Report
BRNI discovery raises hopes for Alzheimer's test. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: